Florence, April 3, 2025
Hospitex International, a company of the ALIKO SCIENTIFIC group, has officially launched Urine24.com, the first digital platform dedicated to urinary cytology testing for early detection of bladder cancer. Now available across Italy, Urine24 sets a new standard in terms of accessibility, precision, and ease of use in cancer prevention.
Meeting a Critical Need in the Italian Market
With more than 29,000 new cases of bladder cancer diagnosed each year and a patient population exceeding 313,000 people, Italy ranks among the countries with the highest incidence of this disease. Urine24 addresses this public health challenge by offering a non-invasive, simple, and highly reliable test for €68.
The potential domestic market is estimated at over €23 million annually, factoring in both new diagnoses and the follow-up of recurrent cases – which affect more than 60% of patients.
Who Should Take the Urine24 Test
Urine24 is especially recommended for:
-
Smokers (over 8.6 million in Italy);
-
Workers exposed to industrial chemicals and dyes;
-
Individuals with chronic urinary infections or recurrent cystitis;
-
Those with a family history of urothelial cancers;
-
People who have undergone pelvic radiotherapy or chemotherapy;
-
All individuals over 50, a high-risk population (over 21 million Italians).
The potential target population – combining smokers and people over 50 – reaches 29.9 million individuals. Even with just 1% participation, the annual market would exceed €20 million.
Advanced Technology for Reliable Diagnostics
The Urine24 test uses liquid-based cytology with thin-layer methodology, enhancing sample quality and reducing false negatives. Results are interpreted according to The Paris System, an internationally recognized standard that ensures accurate identification of cellular abnormalities.
The entire process is conducted from home: the kit is delivered and collected at the patient’s address, and results are sent digitally within a few days.
A Scalable Innovation for Global Impact
Initial feedback has been extremely positive, confirming strong market demand. Hospitex forecasts €3 million in revenue within the next two years in Italy alone.
However, the global potential is even greater: with over 570,000 new bladder cancer cases diagnosed annually worldwide and a growing emphasis on early detection, Urine24 is well-positioned for expansion in strategic markets such as Europe and North America.
In a sector where oncology diagnostics are growing at over 10% annually, Urine24 stands out as a scalable, accessible, and revolutionary solution.
For more information, visit:
👉 www.urine24.com
